Background and Objective: Cognitive impairment is one of the consequencesof substance abuse. Tramadol abuse is a public health problemin Egypt. The objective of this study was to study the effect of tramadol addiction on cognitive functions, determine if cognitive impairment caused by tramadol is reversible or not and to study the impact of other related factors as duration of intake and dose of tramadol on cognition. Methods: This study included 30 patients with active tramadol abuse, 30 patients abstinent from tramadol for 3 to 6 months and 30 control subjects (matched for age, sex, and education) who were recruited from Kasr Al-Aini psychiatric and addiction hospital (from outpatient clinic and inpatient admitted patients), Egypt.The participants were interviewed using Montreal Cognitive Assessmenttest (MoCA), Trail making test A and B and had urine screening for drugs. Results: 53.33%(n=16) of active group had impaired total MoCA scores compared to 10 % (n=3) in control group.This was statistically significant with P value <0.0001.46.67% (n=14) of abstinent group had impaired total MoCA scores compared to 10 % (n=3) in control group. This was statistically significant with P value 0.002. As regard MoCAsubscores; we found statistically significant impairment in delayed recall and verbal fluency subscores in both the active and abstinent group. There was no statistically significant impairment in Trail making tests A and B.Therewas no association between cognitive impairment and sociodemographicor clinical factors. Conclusions: Cognitive impairment occurs commonly among tramadolabusepatients. Memory impairment and verbal fluencyare the most common cognitive domainsto be affected. Cognitive impairment is not reversible after 3 to 6 months.There is no effect of tramadol dose or duration of abuse on cognitive impairment.
INTRODUCTION
Tramadol hydrochloride is a centrallyacting synthetic analogue of codeine; used for the treatment of moderate to severe pain. It has a dual mechanism of action. Tramadol and its active metabolite, O-desmethyl tramadol, bind to μ opioid receptors, thus exerting their effect on GABAergic transmission. They also inhibit reuptake of 5-hydroxy tryptamine (serotonin) and noradrenaline (Shadnia, et al.
2008, and Taghaddosinejad, et al. 2011).
Few works studied the cognitive profile of tramadol dependence however, many studies were done regarding the cognitive profile of other substances of abuse particularly the opioids and cannabis. This can be explained by that tramadol is not a very common drug in the western world and does not represent a medical issue of importance regarding dependence to be a focus for the scientific research unlike in Egypt where it represents a major health issue (Abo-Elmagd, et al. 2013).
SUBJECS AND METHODS Subjects
This study compares between three groups regarding cognitive functions. The first group is composed of 30 patients with two years or more of regular tramadol abuse (Dependency). The second group is composed of 30 patients who are abstinent from tramadol intake for three to six months (early recovery stage). The third group is a control group of 30 persons from relatives of the first and second group who are matched with them regarding age, sex and educational level. Convenient sample was recruited from Kasr Al-Aini psychiatric and addiction hospital (from outpatient clinic and inpatient admitted patients). It was used to assess several domains of cognition such as the short-term memory recall task (5 points) involves two learning trials of five nouns and delayed recall after approximately 5 minutes. Visuospatial abilities are assessed using a clock-drawing task (3 points) and a three-dimensional cube copy (1 point). Multiple aspects of executive functions are assessed using an alternation task adapted from the trail-making B task (1 point), a phonemic fluency task (1 point), and a two-item verbal abstraction task (2 points). Attention, concentration and working memory are evaluated using a sustained attention task (target detection using tapping; 1 point), a serial subtraction task (3 points), and digits forward and backward (1 point each). Language is assessed using a three-item confrontation naming task with low-familiarity animals (lion, camel, rhinoceros; 3 points), repetition of two syntactically complex sentences (2 points), and the aforementioned fluency task. Finally, orientation to time and place is evaluated (6 points N.B. P1 value between "active group" and "control group".P2 value between "abstinent group" and "control group". P3 value between "active group" and "abstinent group". N.B. P1 value between "active group" and "control group".P2 value between "abstinent group" and "control group". P3 value between "active group" and "abstinent group". Regarding cognitive tests:Both active and abstinent group showed significant impairment in total MoCA scores in relation to control group. There was no statistically significant difference between active and abstinent group regarding the total MoCAscores. This can be explained by the long duration of tramadol abuse in both groups (about 7 years) which affects cognitive functions and the short period of abstinence (3-6 months) in the abstinent group which was not sufficient to reverse these cognitive effects of prolonged use of tramadol. Regarding subscores of MoCA, we found statistically significant difference between active group and control group in delayed recall and verbal fluency subscores. We also found significant difference in these two subscores (verbal fluency and delayed recall) between the abstinent and control group. Regarding Trail-A and Trail-B tests scores, we did not find any significant difference between the active and control group or the abstinent and control group or the active and abstinent group. There are few studies that assessed the cognitive effects of tramadol and their results were controversial. Some studies found that tramadol caused cognitive impairment, other studies found that tramadol did not impair cognition. Our results were similar to results of Bassiony and his colleagues(2017). Bassiony 
RESULTS

Sociodemographic characteristics
Clinical characteristics
LIMITATIONS
This was a cross-sectional study and hence could not explain causation of the CI among patients with tramadol abuse. This clinical study included patients with drug-related problems with a high prevalence of comorbidities. Hence, these findings cannot be generalized to the general population. We included first degree relatives of the patients as control subjects. This might represent a potential bias in study design. We included consecutive patients without randomization, and this might lead to a lack of control for all confounders related to CI.
CONCLUSION
Tramadol addiction causes cognitive impairment,mainly verbal fluency and memory impairment. Abstinence from tramadol for 3 to 6 months did not reverse these cognitive impairments. No effect of daily dose of tramadol on cognitive performance. No effect of duration of dependence on tramadol on cognitive performance.
Recommendations
We recommend future studies to: Include larger sample size, use of more detailed assessment tools for more accurate assessment of certain cognitive domains, assessment of cognitive functions after longer period of tramadol abstinence to determine if the cognitive impairments are reversible or not.
